Glaxo inks deal on cancer drug development

Glaxo (GSK) and privately-held U.K. firm Adaptimmune collaborate on developing cell-based cancer therapies in a deal worth as much as $350M. The partnership focuses on Adaptimmune's lead clinical program which is showing promising results in multiple myeloma, melanoma, sarcoma and ovarian cancer. The therapies work by re-engineering the patient's own t-cells to target and destroy cancer cells.

Glaxo could pay over $350M over seven years if certain milestones are met. Adaptimmune will earn single-to-double digit royalties on commercial sales.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs